T-2328

a brain-penetrating antagonist of tachykinin NK1 receptor; structure in first source

Also Known As:

2-fluoro-4'-methoxy-3'-((((2S,3S)-2-phenyl-3-piperidinyl)amino)methyl)-(1,1'-biphenyl)-4-carbonitrile dihydrochloride

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

1.	Ishii, Taketoshi: 2 articles (06/2008 - 01/2008)
2.	Nagasaki, Masaaki: 2 articles (06/2008 - 01/2008)
3.	Okamoto, Masahito: 2 articles (06/2008 - 01/2008)
4.	Saito, Akira: 2 articles (06/2008 - 01/2008)
5.	Taniguchi, Hiroyuki: 2 articles (06/2008 - 01/2008)
6.	Watanabe, Yumi: 2 articles (06/2008 - 01/2008)
7.	Takatsuka, Satomi: 1 article (06/2008)
8.	Asai, Hidetoshi: 1 article (01/2008)
9.	Kiuchi, Satoko: 1 article (01/2008)

1.	Vomiting 01/01/2008 - "T-2328 may have potential as a novel therapeutic agent for the treatment of chemotherapy-induced emesis." 06/01/2008 - "The effect of T-2328 {2-fluoro-4'-methoxy-3'-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1'-biphenyl]-4-carbonitrile dihydrochloride}, a novel tachykinin NK(1)-receptor antagonist, was examined on cisplatin-induced emesis in ferrets. "

1.	Drug Therapy (Chemotherapy)